ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 807.9 USD | +0.05% |
|
+0.58% | +38.59% |
| 28/05 | Annual sales of weight-loss drugs seen hitting $150 billion | RE |
| 28/05 | Weight-loss drug forecasts jump to $150 billion as supply grows | RE |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 34 M€ | +4.49% | - | |
| 25.35% | 129 M€ | +7.99% | - |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.59% | 73TCr | |
| -7.89% | 35TCr | |
| +15.66% | 33TCr | |
| +0.24% | 28TCr | |
| +13.47% | 24TCr | |
| +7.35% | 21TCr | |
| -6.42% | 20TCr | |
| +4.23% | 16TCr | |
| -1.70% | 16TCr | |
| -1.31% | 12TCr |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company
